Editas Medicine (EDIT), a gene editor therapy provider, is getting closer to clinical trials for LCA10, IND in October. With all gene editing companies becoming excluded from future RAC meeting. $EDIT, Editas Medicine, Inc. / H1 The next milestone for EDIT is an IND filing. Mallinckrodt (MNK) reported Q2 revenue of $631.7M, up 5.3% Y/Y. Ofirmev revenue grew 13%, followed by Therakos, up 10.9 percent. Acthar Gel makes the most revenue but fell 8.2%. MNK forecasts net sales growth in the range of 4 – 7 percent. $MNK, Mallinckrodt plc / H1 Non-GAAP was raised to $6.50 - $6.90, up from $6.00 - $6.50. Shorts are getting a big squeeze as the Acthar sales drop-off was offset by other products. Short-covering will continue driving the stock higher. Short float is 33 percent. Berkshire added its bullish view on Teva Pharmaceuticals (TEVA) by adding to its holding. It now owns 43.2 million shares worth over $1 billion. Teva will launch a generic Epipen this year as Mylan (MYL) fails to produce enough, creating a shortage. $TEVA, Teva Pharmaceutical Industries Limited / H1 What are your biotech picks for the month? Previously: $REGN, $EXAS were top picks.Now read this:1,200% return. Wow.Delete Facebook and do thisJD.com dips